Cell and Gene Therapies (CGTs) are revolutionizing medicine by offering long-term remission and even cures for previously untreatable diseases. However, their complex manufacturing processes and temperature-critical cold chain requirements present significant logistical challenges. Unlike traditional pharmaceuticals, CGTs require precise coordination from vein-to-vein, involving cryopreservation, real-time tracking, and close collaboration between manufacturers, hospitals, and specialized logistics providers.

Emerging technologies like AI and machine learning are enhancing supply chain efficiency, while strategic partnerships and robust training are vital for maintaining product integrity and patient safety. Marken leads the way by optimizing cold chain logistics for life-saving therapies.

In this featured article, Marken experts, Rohin Iyer, Senior Director of Cell and Gene Operations, and Kirsty Baxter, Director of Project Management for Cell and Gene Therapies, offer insights into the CGT sector and how Marken bridges logistical gaps to ensure patient access to vital healthcare innovations.

SOURCE: European Biopharmaceutical Review, BIO-Europe Spring Supplement, February 2025, pages 32-34. © Samedan Ltd